^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CXCL12 overexpression

i
Other names: CXCL12, C-X-C Motif Chemokine Ligand 12, Stromal Cell-Derived Factor 1, PBSF, Pre-B Cell Growth-Stimulating Factor, Chemokine (C-X-C Motif) Ligand 12, Intercrine Reduced In Hepatomas, SCYB12, TPAR1, SDF1, IRH, C-X-C Motif Chemokine 12, CXCL12, SDF-1a, SDF-1b, TLSF-A, TLSF-B, HSDF-1, SDF1A, SDF1B, SDF-1, TLSF, HIRH
Entrez ID:
Related biomarkers:
over1year
Key Subsets of Immune Cells in Bone Marrow Myeloid Compartment Indicate Degree of Tumor Infiltration and Avenues for Successful Immunotherapy in Multiple Myeloma (ASH 2022)
In multiple single cell experiments measuring effectiveness of Iberdomide in combination with Dexamethasone and an additional experiment comparing aged and untreated Vk*MYC mice with multiple myeloma (MM), key compositional patterns emerge in the murine bone marrow niche. Cell Adhesion & Migration vol. 6 220–230 (2012).
IO biomarker
|
CRBN (Cereblon) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CCL5 (Chemokine (C-C motif) ligand 5) • APOE (Apolipoprotein E) • VCAM1 (Vascular Cell Adhesion Molecule 1)
|
CXCL12 expression • CXCL12 overexpression
|
iberdomide (CC-220)
2years
C-X-C motif chemokine ligand 12 (CXCL12)/C-X-C motif chemokine receptor 7(CXCR7) regulates epithelial-mesenchymal transition process and promotes the metastasis of esophageal cancer by activating signal transducer and activator of transcription 3 (STAT3) pathway. (PubMed, Bioengineered)
Inhibition of the STAT3 pathway using AZD9150 weakened the accelerated effects of CXCL12/CXCR7 on the growth and metastasis of esophageal cancer in vitro and in vivo. In conclusion, our research revealed that CXCL12/CXCR7 regulates EMT and other malignant processes by activating the STAT3 pathway to accelerate the growth and metastasis of esophageal cancer.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • ACKR3 (Atypical Chemokine Receptor 3)
|
CXCL12 expression • CXCL12 overexpression
|
danvatirsen (AZD9150)
over2years
[VIRTUAL] IMPROVED ORAL CAVITY SCC THERAPEUTIC RESPONSE THROUGH COMBINED TARGETING OF CXCR4 AND PD-L1 (AHNS 2021)
We have developed cisplatin resistant variants of mouse oral cancer cell lines (MOC1 and MOC2) to evaluate combined CXCR4 and PD-L1 blockade (AMD 3100 and Nivolumab). This model was used to determine whether CXCR4 inhibition could enhance anti-PD-L1 efficacy. Combinatorial blockade of both pathways provided better outcomes relative to anti-PD-L1 treatment and extended our understanding of immunotherapy resistance.
PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • IL2RA (Interleukin 2 receptor, alpha) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CD4 (CD4 Molecule)
|
CXCL12 overexpression • CXCR4 expression
|
Opdivo (nivolumab) • cisplatin • plerixafor
3years
A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment. (PubMed, Proc Natl Acad Sci U S A)
In in vitro and in vivo hepatocellular carcinoma mouse models it can significantly suppress primary tumor growth, prevent distant metastasis/cell migration, reduce angiogenesis, and normalize the immunosuppressive tumor microenvironment by reducing tumor-associated macrophages (TAMs) infiltration, reprogramming TAMs toward an immunostimulatory phenotype and promoting cytotoxic T cell infiltration into tumor. Although BPRCX807 treatment alone prolongs overall survival as effectively as both marketed sorafenib and anti-PD-1, it could synergize with either of them in combination therapy to further extend life expectancy and suppress distant metastasis more significantly.
Journal
|
CXCL12 (C-X-C Motif Chemokine Ligand 12)
|
CXCL12 overexpression
|
sorafenib
over3years
LncRNA SNHG1 promotes neuronal injury in Parkinson's disease cell model by miR-181a-5p/CXCL12 axis. (PubMed, J Mol Histol)
Besides, SNHG1 could indirectly regulate CXCL12 expression via miR-181a-5p. We demonstrated that SNHG1 promoted MPP induced neuronal injury in neuroblastoma cells by regulating miR-181a-5p/CXCL12 axis, suggesting SNHG1 might contribute to the development of PD, which provided a novel insight into the pathogenesis and treatment of PD.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CASP3 (Caspase 3)
|
CXCL12 overexpression